Geneva (Switzerland): The World Health Organisation (WHO) has approved Covid-19 vaccine Covovax, which is manufactured by the Serum Institute of India under licence from US company Novavax, for emergency use.
WHO approves emergency use of Covid-19 vaccine Covovax
Geneva (Switzerland): The World Health Organisation (WHO) has approved Covid-19 vaccine Covovax, which is manufactured by the Serum Institute of India under licence from US company Novavax, for emergency use.
Covavax is the Indian version of the Novavax vaccine brought in India by the Serum Institute of India for children.[/caption]
Also read | SC refuses to interfere with HC order staying cancellation of Orbit bus permits
The WHO approval is a prerequisite for being on the COVAX drug list, as well as for international procurement.
According to the statement, Covid-19 vaccine Covovax was assessed under the WHO EUL procedure based on the review of data on quality, safety and efficacy, a risk management plan, programmatic suitability, and manufacturing site inspections carried out by the Drugs Controller General of India.
[caption id="" align="aligncenter" width="710"]
The WHO approval is a prerequisite for being on the COVAX drug list, as well as for international procurement.[/caption]
Also read | Australia bouncy castle accident that left five children dead; know more
The Technical Advisory Group for Emergency Use Listing (TAG-EUL), convened by WHO and made up of experts from around the world, has determined that the vaccine meets WHO standards for protection against Covid-19, that the benefit of the vaccine far outweighs any risks, and that the vaccine can be used globally.
Covavax is the Indian version of the Novavax vaccine brought in India by the Serum Institute of India for children.
[caption id="" align="aligncenter" width="1500"]
The vaccine, named CovovaxTM, is produced by the Serum Institute of India under licence from Novavax and is part of the COVAX facility portfolio.[/caption]
-PTC News
